The Future of R&D in Pharmaceutical Industry in 2025

From ScenarioThinking
Jump to navigation Jump to search

EMBA09 team:
Murat Akguc
Ruth Donners
Peter Friedl
Susan Liu

Work under construction. In case you have any questions, additions or comments, please do not edit these pages, but you are more than welcome to contact us.

Scenarios.



To be added

Research Questions.

  • Move to emerging markets (subquestions: what is government stance, how is local infrastructure (ie. can you get the drugs to the people?)?
  • What are regulatory issues regarding local registration of the drug?
  • No more blockbusters, even focus on generics, or are there still enough other diseases to cure without simply incrementally improving existing drugs?
  • Generics vs. Patents? What will the IP landscape be?

Driving forces.

Edited existing ones

• Increasing potential to grow based on new available technology
• Struggling old world economy
• Increasing Empowerment of Consumers in Healthcare System
• Continuously growing demand for new medical applications
• The increasing gap between developed, emerging and poor economies
• The increasing globalization of markets
• Power of the United Nations
• Legal Restrictions for Biotech increasing in certain countries, decreasing in others


Added new ones

• IP rights
• Logistics/Distribution
• Illnesses of global importance/Pandemics
• Research budget in pharmaceutical industry
• Effect of development of health care system in emerging market countries to existing pharmaceutical industry
• Unification of regulatory approval
• Increasing Competitiveness through innovation in biotechnology
• Changing business models for pharmaceutical industry


Resources

Retrieved from "https://www.scenariothinking.org/index.php?title=The_Future_of_R%26D_in_Pharmaceutical_Industry_in_2025&oldid=30042"